Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Exclusion Criteria

• •Patients with non-secretory myeloma
• •Severe psychological or medical illness
• •Pregnant or lactating women
• •Subjects with \> Grade I toxicity by NCI-CTC v 3.0
• •Subjects with prognosis \< 6 months
• •2\. For Vaccination:
• •\< 75 mg of idiotype protein purified from the patients serum
• •\< 25 million allogeneic idiotype-pulsed dendritic cells produced for vaccination
• •Evidence of grade II-IV acute GVHD (defined in section 5E)
• •Patients with evidence of myeloma disease progression as (defined below)
• •Severe psychological or medical illness or concomitant medications which may interfere with the study as determined by the clinical investigator
• •Patients on any other investigational agents
• •Pregnant or lactating women
• •Patients on any therapy for multiple myeloma or any chemotherapy drug, or immunomodulatory agent for treatment of multiple myeloma (e.g. thalidomide)
• •Any patient on more than two of the following immunosuppressive agents or at a dose greater than that indicated for a single immunosuppressive agent:
• •1. Mycophenolate Mofetil (MMF)- no greater than 1000mg twice a day
• •2. Prednisone- no greater than .5mg/kg/day
• •3. Cyclosporine- no greater than 300mg/day
• •4. Tacrolimus (FK506)- no greater than 4mg/day